stomach cramps from tirzepatide Does make you tired? Why it happens and what to do Does Tirzepatide Injection Cause Vomiting?,

Will I need to change my diet and exercise habits

This is particularly important because carrying extra weight or having obesity is a risk factor for type 2 diabetes

LBA 55, LBA 89 Hong, D

Neumiller, PharmD, CDE, FAADE Associate Professor Department of Pharmacotherapy College of Pharmacy and Pharmaceutical Sciences Washington State University Spokane, Washington FACULTY DISCLOSURE STATEMENTS Mr

Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations